A Multinational Investigation of the Impact of Subcutaneous Sumatriptan

Dahlöf, Carl; Bouchard, Josée; Cortelli, Pietro; Heywood, J; Jansen, Josephine; Pham, Sissi V.; Hirsch, Jameson K.; Adams, Jim; Dw, Miller

doi:10.2165/00019053-199700111-00005

Cited by 42 publications

(26 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Triptans are widely recommended for M since studies have shown that their use increases productivity at work and improves the quality of life of M sufferers [26]. However, studies worldwide show that the majority of M patients are using OTCs and the minority is using triptans [2–6, 17, 27, 28].…”

Section: Discussionmentioning

confidence: 99%

Treatment of migraine and tension-type headache in Croatia

et al. 2010

View full text Add to dashboard Cite

The aim of this study was to assess the treatment patterns of migraine and tension-type headache in the Croatian population. Analysis included the proportion of patients who were taking specific antimigraine therapy and the number of tablets per attack per month, the proportion of patients who were taking prophylactic therapy or using alternative treatment methods and their satisfaction with the treatment. The design of the study was a cross-sectional survey. Self-completed questionnaires were randomly distributed to adults >18 years of age in the Croatian population. A total of 616 questionnaires were analyzed: 115 patients with migraine (M), 327 patients with tension-type headache (TTH), and 174 patients with probable migraine (PM) and TTH. Specific antimigraine therapy was taken by half of patients with migraine: 35.7% of patients used triptans and 21.7% ergotamines. Prophylactic treatment had been used by 13.9% of M, 1.2% of TTH, and 6.9% of PM patients. Alternative methods of treatment were tried by 27% of M and TTH patients. Only 16.8% of patients with M pay regular visits to physicians, while 36.3% never visited a physician. More than half of TTH patients have never visited a physician. The majority of patients are only partially satisfied with their current treatment, and almost one-third are not satisfied. Results of this study indicate that the treatment of primary headaches in Croatia should be improved.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment of migraine and tension-type headache in Croatia

et al. 2010

View full text Add to dashboard Cite

show abstract

“…The MSQ has been administered in several efficacy trials of migraine treatment and has been has shown to be responsive to treatment effects [17, 18, 23]. Results from a study of 119 migraineurs recruited at 4 headache clinics revealed that the effect sizes of the MSQ were moderate to large at 4 and 12 weeks [24].…”

Section: Methodsmentioning

confidence: 99%

The psychometric properties of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ) in chronic migraine patients

et al. 2012

View full text Add to dashboard Cite

Objective The Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ) has been shown to have good psychometric performance in measuring headache impact in migraine patients, but its properties specifically in chronic migraine (CM) patients are unknown. The objective of this study was to evaluate the psychometric properties of the MSQ in a group of CM patients undergoing prophylactic treatment. Methods Measurement properties of the MSQ were examined using two international, multicenter, randomized clinical trials evaluating onabotulinumtoxinA as headache prophylaxis in CM patients (N = 1,376). Confirmatory factor analysis (CFA) was used to test the latent structure of the MSQ in CM patients. The reliability, convergent and discriminant validity, and responsiveness of the MSQ were assessed. Results CFA confirmed the currently proposed three-factor MSQ latent structure across the two studies. Good reliability was observed for all three MSQ scales, across studies and time points. MSQ scale scores strongly correlated with the scores of the Headache Impact Test-6 (HIT-6). Analysis of knowngroups validity indicated that MSQ scale scores discriminated between groups of patients differing in their 28-day headache frequency were as follows\10, 10-14, and C15 days, and the sample-derived quartiles of the total cumulative hours of headache were as follows \140, 140 to \280, 280 to \420, and C420 h (p \ 0.0001), across both studies and time points. MSQ change scores were higher in magnitude in groups experiencing greater decline in headache frequency (p \ 0.001). Conclusion The MSQ is a psychometrically valid tool that can be used to reliably measure the impact of migraine among CM patients.

show abstract

“…SF-36 and MSQ were found to be able to demonstrate improvement following repetitive administration of triptans in open trials (186)(187)(188).…”

Section: Health-related Quality Of Life (Ability To Function In Dailymentioning

confidence: 98%

Guidelines for controlled trials of drugs in migraine: Third edition. A guide for investigators

Tfelt‐Hansen

Pascual

Ramadan³

et al. 2012

Cephalalgia

322

213

View full text Add to dashboard Cite

A Multinational Investigation of the Impact of Subcutaneous Sumatriptan

Cited by 42 publications

References 11 publications

Treatment of migraine and tension-type headache in Croatia

Treatment of migraine and tension-type headache in Croatia

The psychometric properties of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ) in chronic migraine patients

Guidelines for controlled trials of drugs in migraine: Third edition. A guide for investigators

Contact Info

Product

Resources

About